Loading
HiberCell
HiberCell is a New York biotech working on the biology of dormant, disseminated cancer cells; its yeast beta-glucan immunotherapy imprime PGG, inherited from Biothera, reached late-stage trials with checkpoint inhibitors.
Also called: HiberCell, Inc.Biothera Pharmaceuticals
Overview
HiberCell, founded in 2019 in New York, develops therapies against cancer dormancy and relapse and acquired Biothera Pharmaceuticals, whose imprime PGG, a yeast-derived beta-glucan that primes innate immune cells, had been tested with pembrolizumab in breast cancer and melanoma. Its PERK inhibitor and other programmes are in early trials, and the Biothera-era phase 3 record sits on ClinicalTrials.gov under the company as lead sponsor.
Connected
5Similar pages
- CompanyPregLem
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
hibercell.com · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-17 · Jude Gomila · Link orphan sponsor companies, repoint AAA trials to Nova… · diff · file
Sourced, not expert-reviewed